Department of Infectious Diseases, Hospital Universitario Ramón y Cajal, IRYCIS, Universidad de Alcalá and CIBERINFEC, Madrid, Spain.
Department of Infectious Diseases, Hospital Universitario Ramón y Cajal, IRYCIS, Universidad de Alcalá and CIBERINFEC, Madrid, Spain.
J Infect. 2022 Jul;85(1):86-89. doi: 10.1016/j.jinf.2022.04.041. Epub 2022 Apr 29.
Variations in the ACE2 activity in saliva could explain the striking differences of susceptibility to infection and risk of severe disease.
We analyze the activity of ACE2 in saliva in different population groups across a wide age range and disease status during April to June 2020, before SARS-CoV-2 vaccine implementation, and we establish differences between infected people and participants considered resistant (highly exposed healthcare workers and children who cohabited with parents with COVID-19 without isolation and remain IgG negative).
We included 74 adults, of which 47 (64%) were susceptible and 27 (36%) were resistant, and 79 children, of which 41 (52%) were susceptible and 38 (48%) were resistant. Resistant adults have significantly lower ACE2 activity in saliva than susceptible adults and non-significant higher values than susceptible and resistant children. ACE2 activity is similar in the susceptible and resistant pediatric population (p = 0.527). In contrast, we observe an increase in activity as the disease's severity increases among the adult population (mild disease vs. severe disease, 39 vs. 105 FU, p = 0.039; severe disease vs. resistant, 105 vs. 31 FU, p < 0.001).
using an enzymatic test, we show that ACE2 activity in saliva correlates with the susceptibility to SARS-Cov-2 infection and disease severity. Children and adults with low-susceptibility to SARS-Cov-2 infection showed the lowest ACE2 activity. These findings could inform future strategies to identify at-risk individuals.
唾液中 ACE2 活性的差异可能解释了对感染的易感性和严重疾病风险的巨大差异。
我们在 2020 年 4 月至 6 月 SARS-CoV-2 疫苗实施前,分析了不同人群在广泛年龄范围内和疾病状态下唾液中 ACE2 的活性,并确定了感染者和被认为具有抵抗力的参与者(高暴露医护人员和与 COVID-19 父母同住但未隔离且 IgG 仍为阴性的儿童)之间的差异。
我们纳入了 74 名成年人,其中 47 名(64%)易感,27 名(36%)具有抵抗力,79 名儿童,其中 41 名(52%)易感,38 名(48%)具有抵抗力。具有抵抗力的成年人的唾液 ACE2 活性明显低于易感成年人,但显著高于易感和抵抗力儿童。易感和具有抵抗力的儿科人群的 ACE2 活性相似(p=0.527)。相比之下,我们观察到成年人中随着疾病严重程度的增加 ACE2 活性增加(轻症 vs. 重症,39 vs. 105 FU,p=0.039;重症 vs. 抵抗力,105 vs. 31 FU,p<0.001)。
我们使用酶促试验表明,唾液中 ACE2 的活性与 SARS-CoV-2 感染的易感性和疾病严重程度相关。对 SARS-CoV-2 感染低易感性的儿童和成年人显示出最低的 ACE2 活性。这些发现可能为未来识别高危个体的策略提供信息。